Transdermal Diagnostics Secures Major SBRI Healthcare Grant to Advance Non-Invasive Glucose Monitoring for Children and Young People
Bristol, UK – 04/02/2025 – Transdermal Diagnostics, a pioneering innovator in non-invasive health monitoring, has been awarded £800,000 in funding through the prestigious SBRI Healthcare initiative. This funding will accelerate the development and commercialization of its groundbreaking needle-free Continuous Glucose Monitoring (CGM) system, designed to transform diabetes management for children and young people.
As part of a national initiative led by SBRI Healthcare and the Accelerated Access Collaborative (AAC), in partnership with the Health Innovation Network, this award recognizes Transdermal Diagnostics’ potential to deliver a game-changing solution for the 36,000 children and young people in the UK living with diabetes.
Revolutionizing Diabetes Care with Non-Invasive Technology
The company’s next-generation skin-wearable features disposable sensor patches and a rechargeable transmitter, enabling seamless, pain-free blood sugar monitoring through a user-friendly mobile app. Unlike traditional CGMs that rely on needle-based sensors, Transdermal Diagnostics’ proprietary technology extracts glucose through the skin without breaking its barrier, eliminating pain, reducing skin damage, and increasing patient adherence.
“This funding marks a significant milestone in our journey to redefine glucose monitoring for children and young people,” said Prof. Richard Guy, Director and Co-founder of Transdermal Diagnostics. “We are committed to bringing to market a truly non-invasive alternative that improves quality of life and empowers young patients and their families with real-time, needle-free glucose monitoring.”
Positioned for Growth and Market Expansion
“The affordability of Transdermal Diagnostics' smart patches will democratize access to CGM for all those in need. With a low cost of goods and a scalable manufacturing process, this technology presents an unparalleled opportunity for the industry to bring next-generation diabetes care to a much wider population,” said Giles Hamilton, Chair of Transdermal Diagnostics’ Board of Directors.
This latest funding from SBRI Healthcare provides a springboard for further product development, clinical validation, and strategic partnerships. With a growing global diabetes market projected to reach $140 billion by 2030, Transdermal Diagnostics is uniquely positioned for commercial success, offering a disruptive solution that addresses critical pressure points in diabetes management.
“Investors and industry partners have a unique opportunity to be part of a high-growth, high-impact innovation in digital health and remote patient monitoring,” said Dr. Luca Lipani, Co-founder and CEO of Transdermal Diagnostics. “There is a clear clinical need for a painless and accessible glucose monitoring solution, and our non-invasive CGM technology is designed not just to improve diabetes management but to drive a paradigm shift in how multiple chronic conditions are managed.”
With real-world implementation on the horizon, Transdermal Diagnostics invites strategic investors and healthcare innovators to join its mission to make glucose monitoring truly painless, accessible, and more effective than ever before.
Transdermal Diagnostics is at the forefront of non-invasive health monitoring, developing innovative skin-wearable solutions that eliminate the need for needles while delivering continuous, real-time biomarker tracking. The company’s flagship glucose monitoring platform is poised to disrupt the diabetes care market, offering a pain-free, user-friendly alternative to traditional CGMs.
For investor inquiries, partnerships, or media requests, please contact: enquiries@transdermal-diagnostics.com
About SBRI Healthcare
SBRI (Small Business Research Initiative) Healthcare provides funding and support to innovators to develop solutions that tackle existing unmet needs faced by the NHS. The programme aims to improve patient care, increase efficiency in the NHS, and support the UK economy. The programme provides funding and support to early-stage projects enabling testing for business feasibility and technology development, as well as to more mature products to support real world implementation studies. SBRI Healthcare is funded by the Accelerated Access Collaborative and delivered in partnership with the Health Innovation Network.
About the Accelerated Access Collaborative
The Accelerated Access Collaborative is a unique partnership between patient groups, government bodies, industry and the NHS. It delivers ambitious programmes to ensure the NHS is in the best place to improve patient outcomes and reduce health inequalities through research and innovation. It does this by identifying the best new medicines, medical devices, diagnostics and digital products. It supports providers and integrated care systems to make them available to patients as quickly as possible.
About the Health Innovation Network
There are 15 health innovation networks across England, established by NHS England in 2013 to spread innovation at pace and scale – improving health and generating economic growth. Each health innovation network works across a distinct geography serving a different population in each region. As the only bodies that connect NHS and academic organisations, local authorities, the third sector and industry, health innovation networks are catalysts that create the right conditions to facilitate change across whole health and social care economies, with a clear focus on improving outcomes for patients.
